Year 2022 Vol. 30 No 4




Pirogov Russian National Research Medical University, Moscow,
Russian Federation

The use of anticoagulants and disaggregant agents in patients with peripheral atherosclerosis has been an integral part of therapy for many years. . The role and their combination has undergone numerous changes with the development of understanding of their mechanisms of action and influence on peripheral hemodynamics. In addition, the use of anticoagulants and disaggregant agents plays a decisive role in patients with critical lower limb ischemia who underwent reconstruction of the peripheral arterial bed. In the postoperative period in many cases the precisely well-chosen tablet therapy can be the very key link in saving the limb. Besides, atherosclerosis is multi-organ disease that usually affects the coronary and cerebral pools. Pathological processes in these systems can significantly affect the health and quality of life, are often disabling nature, often threatening the patients life. Today the inconsistency of clinical and practical information about the effectiveness of various schemes of antiplatelet and anticoagulant therapy is beyond doubt. For example, the required duration of tablet therapy is not supported by reliable studies. A large number of outdated studies, their insufficient scale are consided to be a stumbling block for determining the current unified standard of perioperative therapy for patients with peripheral atherosclerosis. The identification of the ideal scheme will allow improving the immediate and remote results of surgical interventions, but also to carry out an effective prevention of formidable complications of the cardiovascular system as a whole.

Keywords: peripheral artery atherosclerosis, low limb ischemia, femoropopliteal bypass, low limb amputation, anticoagulants, disaggregants
p. 382-391 of the original issue
  1. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UK, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013 Oct 19;382(9901):1329-40. doi: 10.1016/S0140-6736(13)61249-0
  2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015 Apr 24;116(9):1509-26. doi: 10.1161/CIRCRESAHA.116.303849
  3. Pokrovskii AV, red. Klinicheskaia angiologiia, Moscow, RF: Meditsina; 2004. T. 2. 888 p. (In Russ.)
  4. Panteleev MA, Sveshnikova AN. Trombotsity i gemostaz. Onkogematologiia. 2014;9(2):65-73. doi: 10.17650/1818-8346-2014-9-2-65-73 (In Russ.)
  5. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994 May 19;330(20):1431-38. doi: 10.1056/NEJM199405193302008
  6. Hess CN, Norgren L, Ansel GM, Capell WH, Fletcher JP, Fowkes FGR, Gottsäter A, Hitos K, Jaff MR, Nordanstig J, Hiatt WR. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation. 2017 Jun 20;135(25):2534-55. doi: 10.1161/CIRCULATIONAHA.117.024469
  7. Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12;70(11):1368-75. doi: 10.1016/j.jacc.2017.07.768
  8. Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2016 Aug 30;116(3):544-53. doi: 10.1160/TH15-12-1000
  9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists Collaboration. BMJ. 2002 Jan 12;324(7329):71-86. doi: 10.1136/bmj.324.7329.71
  10. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010 Mar 3;303(9):841-48. doi: 10.1001/jama.2010.221
  11. Sigvant B, Kragsterman B, Falkenberg M, Hasvold P, Johansson S, Thuresson M, Nordanstig J. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016 Oct;64(4):1009-1017.e3. doi: 10.1016/j.jvs.2016.03.429
  12. McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R. Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg. 1991 Jan;13(1):150-61; discussion 161-2. doi: 10.1016/0741-5214(91)90022-M
  13. Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2015 Feb 19;2015(2):CD000535. doi: 10.1002/14651858.CD000535.pub3
  14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3
  15. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Mar 21;135(12):e726-e779. doi: 10.1161/CIR.0000000000000471
  16. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009 Jan;30(2):192-201. doi: 10.1093/eurheartj/ehn534
  17. Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027
  18. Gratsiansky NA. Antiplatelet therapy in coronary heart disease. some problems and achivements .Aterotromboz. 2010;50(6):4-21. (In Russ.)
  19. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009 Feb;30(4):426-35. doi: 10.1093/eurheartj/ehn562
  20. Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008 Aug 26;52(9):734-39. doi: 10.1016/j.jacc.2008.05.032
  21. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg. 2002 Mar;35(3):413-21. doi: 10.1067/mva.2002.121847
  22. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327
  23. Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32-40. doi: 10.1056/NEJMoa1611688
  24. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007 Jul 19;357(3):217-27. doi: 10.1056/NEJMoa065959
  25. Anand SS. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral anticoagulants or Aspirin study). Lancet. 2000;355:346-51.
  26. Monaco M, Di Tommaso L, Pinna GB, Lillo S, Schiavone V, Stassano P. Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. J Vasc Surg. 2012 Jul;56(1):96-105. doi: 10.1016/j.jvs.2012.01.004
  27. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, ODonnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-30. doi: 10.1056/NEJMoa1709118
  28. Vanassche T, Verhamme P, Anand SS, Shestakovska O, Fox KA, Bhatt DL, Avezum A, Alings M, Aboyans V, Maggioni AP, Widimsky P, Berkowitz SD, Yusuf S, Connolly SJ, Eikelboom JW, Bosch J. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020 Feb;27(3):296-307. doi: 10.1177/2047487319882154
  29. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139
  30. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819
  31. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052
Address for correspondence:
117997, Russian Federation,
Moscow, st. Ostrovityanov, house 1,
Russian National Research
Medical University N.I. Pirogov,
Department of Faculty Surgery No. 1
of the Faculty of Medicine,
tel: +7 916 824-07-31,
Muravyov Maxim N.
Information about the authors:
Virgansky Anatoly O., MD, Professor of the Department of Faculty Surgery No. 1 of the Medical Faculty of the Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian Federation.
Muravyov Maksim N., Post-Graduate Student of the Department of Faculty Surgery No. 1 of the Medical Faculty of the Russian National Research Medical University Named after N.I. Pirogov, Moscow, Russian Federation.
Panfilov Vladislav A., Cardiovascular Surgeon, CSH im. V.V. Vinogradova, Moscow, Russian Federation.
Romanenko Konstantin V., Cardiovascular Surgeon, Head of the Department of Vascular Surgery, CCH Named after V.V. Vinogradova, Moscow, Russian Federation.
Contacts | ©Vitebsk State Medical University, 2007-2023